Autolus Therapeutics (AUTL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.19
- Surprise
- —
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est — benzinga, 2026-08-11
- Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates AUTL Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-16.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $8.72 vs price $2.41 — ratio 3.6×). Rejected, falling back to technical TP.
- Quality below floor (1.7 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.41
- Price target
- $2.53
- Stop
- $2.24
- Upside to target
- +5.0%
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
AUTL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $641.5M
- P/E (fwd)
- -3.8
- 52-week range
- $1.18–$2.58
- Off 52-week high
- 6.6%
- RSI (14)
- 69
- Volume vs avg
- 0.70×
- Score today
- 5.3/10